Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical Cord Mesenchymal Stem Cells
Retrieved on:
Monday, April 13, 2020
Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.
Key Points:
- Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.
- Respiratory distress kills hundreds of thousands of people each year worldwide.
- Physicians have reported to Predictive that over 1,100 patients have been treated with CoreCyte via intravenous administration.
- Predictives signature products are uniquely born from the Whartons jelly layer of the umbilical cord and amniotic fluid and tissue.